Structural basis for binding of the renal carcinoma target hypoxia‐inducible factor 2α to prolyl hydroxylase domain 2
Proteins: Structure, Function, and Bioinformatics · 2023
DOI: 10.1002/prot.26541 ↗At a glance
Journal article in Proteins: Structure, Function, and Bioinformatics, 2023. Written by William D Figg and 6 co-authors. Institution: Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford, Institute for Antimicrobial Research, University of Oxford, Oxford, UK. Major MEDLINE topics: Carcinoma, Renal Cell, Kidney Neoplasms. Cited 15 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0). Funded by: Cancer Research UK, Biotechnology and Biological Sciences Research Council, Wellcome Trust.
Abstract (original language)
The hypoxia‐inducible factor (HIF) prolyl‐hydroxylases (human PHD1‐3) catalyze prolyl hydroxylation in oxygen‐dependent degradation (ODD) domains of HIFα isoforms, modifications that signal for HIFα proteasomal degradation in an oxygen‐dependent manner. PHD inhibitors are used for treatment of anemia in kidney disease. Increased erythropoietin (EPO) in patients with familial/idiopathic erythrocytosis and pulmonary hypertension is associated with mutations in EGLN1 (PHD2) and EPAS1 (HIF2α); a drug inhibiting HIF2α activity is used for clear cell renal cell carcinoma (ccRCC) treatment. We report crystal structures of PHD2 complexed with the C‐terminal HIF2α‐ODD in the presence of its 2‐oxoglutarate cosubstrate or N‐oxalylglycine inhibitor. Combined with the reported PHD2.HIFα‐ODD structures and biochemical studies, the results inform on the different PHD.HIFα‐ODD binding modes and the potential effects of clinically observed mutations in HIFα and PHD2 genes. They may help enable new therapeutic avenues, including PHD isoform‐selective inhibitors and sequestration of HIF2α by the PHDs for ccRCC treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford, Institute for Antimicrobial Research, University of Oxford, Oxford, UK.
- Institute of Natural Medicine, University of Toyama, Toyama, Japan.
ORCID profiles: William D Figg, Giorgia Fiorini, Rasheduzzaman Chowdhury, Yu Nakashima, Anthony Tumber, Michael A McDonough, Christopher J Schofield
Funding
- Cancer Research UK
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- Diamond Light Source
Cite
APA
Figg, W. D., Fiorini, G., Chowdhury, R., Nakashima, Y., Tumber, A., McDonough, M. A., & Schofield, C. J. (2023). Structural basis for binding of the renal carcinoma target hypoxia‐inducible factor 2α to prolyl hydroxylase domain 2. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.26541
Vancouver
Figg WD, Fiorini G, Chowdhury R, Nakashima Y, Tumber A, McDonough MA, et al. Structural basis for binding of the renal carcinoma target hypoxia‐inducible factor 2α to prolyl hydroxylase domain 2. Proteins: Structure, Function, and Bioinformatics. 2023. doi:10.1002/prot.26541
BibTeX
@article{Figg2023,
author = {Figg, William D and Fiorini, Giorgia and Chowdhury, Rasheduzzaman and Nakashima, Yu and Tumber, Anthony and McDonough, Michael A and Schofield, Christopher J},
title = {Structural basis for binding of the renal carcinoma target hypoxia‐inducible factor 2α to prolyl hydroxylase domain 2},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2023},
doi = {10.1002/prot.26541}
}
EUVIMED